pharma

NATCO Pharma Wins Patent War against Teva Pharmaceuticals.

Leave a Comment / Patent Research / By ipmetrix / Copaxone, multiple sclerosis, Natco, pharma, Teva

Hyderabad based-Natco Pharma has won a patent battle against Israeli drug giant Teva Pharmaceuticals, over Copaxone, a drug used to treat multiple sclerosis. Natco markets Copaxone (Glatiramer Acetate) used in the treatment of relapsing-remitting multiple sclerosis — in the US market. The drug\’s patent to Teva is set to expire in May. Teva appealed The …

NATCO Pharma Wins Patent War against Teva Pharmaceuticals. Read More »

US and India sparring over IPR and trade practices

Leave a Comment / News Updates / By ipmetrix / Bayer, india, Natco, Nexavar, pharma, us

US and India have been sparring over IPR and trade practices. To begin with US claimed that India’s IPR regime discriminated against U.S. companies, especially in the pharmaceuticals sector, and had expressed concerns over issuing a compulsory license (CL), to Hyderabad-based Natco Pharma to manufacture and produce cancer drug Nexavar at a price 30 times …

US and India sparring over IPR and trade practices Read More »

What is your IP portfolio? ipMetrix provides value-added research and strategy for all IP classes.